62 results
PRE 14A
BDTX
Black Diamond Therapeutics Inc
12 Apr 24
Preliminary proxy
4:48pm
, or ESG, strategy, initiatives, and policies, including matters related to environmental, health and safety, diversity and inclusion, and ethics … strategy and planning including product safety, human capital management, and ethics and compliance. These are among the areas of focus
8-K
EX-99.1
BDTX
Black Diamond Therapeutics Inc
12 Mar 24
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
7:17am
activity in heavily pretreated patients. BDTX-1535 was shown to be generally well tolerated, with no new safety signals observed.
Black Diamond
8-K
EX-99.2
fkcfn6wnmrnledm5x
4 Jan 24
Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones
8:07am
8-K
0wqlwrgxgq7ij
13 Dec 23
Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM
7:08am
8-K
EX-99.1
wq1wk8
13 Dec 23
Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM
7:08am
8-K
EX-99.1
yr7nb
6 Nov 23
Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
7:10am
8-K
EX-99.1
1ivzh7au
11 Aug 23
Black Diamond Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
7:22am
8-K
EX-1.1
g5vbi6
30 Jun 23
Entry into a Material Definitive Agreement
4:03pm
424B5
3tf 43inrxwxq
30 Jun 23
Prospectus supplement for primary offering
4:01pm
424B5
zpr9tr6di cq7cy73x
29 Jun 23
Prospectus supplement for primary offering
6:02am
8-K
EX-99.1
jqy8k1
27 Jun 23
Regulation FD Disclosure
7:11am
8-K
ng96nq8cl2 h6xc12wb
27 Jun 23
Regulation FD Disclosure
7:11am
8-K
EX-99.1
11tnxf8wz5
9 May 23
Black Diamond Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
7:43am